BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Shanghai Vitalgen BioPharma Co.\, Ltd. readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of studies Shanghai Vitalgen BioPharma Co.\,
  Ltd.'s drugs run\, from ClinicalTrials.gov estimates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT07414290-1718@assetmemo.bio
DTSTAMP:20261121T010844Z
DTSTART;VALUE=DATE:20270901
DTEND;VALUE=DATE:20270902
SUMMARY:VGN-R08b: Phase 1/2 readout est. (NCT07414290)
DESCRIPTION:VGN-R08b\, phase 1/2\, Parkinson's Disease.\nStudy: A Trial to 
 Evaluate Safety and Efficacy of a Product Named VGN-R08b in Parkinson's Di
 sease Patients With GBA1 Mutations\nEstimated primary completion: 1 Septem
 ber 2027. This is a ClinicalTrials.gov estimate\, not a confirmed readout 
 date\, and it can move.\nDrug page: https://assetmemo.bio/drug/vgn-r08b#up
 coming-events\nRegistry record: https://clinicaltrials.gov/study/NCT074142
 90
URL:https://assetmemo.bio/drug/vgn-r08b#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07603050-1718@assetmemo.bio
DTSTAMP:20261121T010844Z
DTSTART;VALUE=DATE:20280529
DTEND;VALUE=DATE:20280530
SUMMARY:VGN-R08b: Phase 1/2 readout est. (NCT07603050)
DESCRIPTION:VGN-R08b\, phase 1/2.\nStudy: A Phase I/II Clinical Study to Ev
 aluate the Safety and Efficacy of VGN-R08b in Patients With Type III Gauch
 er's Disease\nEstimated primary completion: 29 May 2028. This is a Clinica
 lTrials.gov estimate\, not a confirmed readout date\, and it can move.\nDr
 ug page: https://assetmemo.bio/drug/vgn-r08b#upcoming-events\nRegistry rec
 ord: https://clinicaltrials.gov/study/NCT07603050
URL:https://assetmemo.bio/drug/vgn-r08b#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
